secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indivior Pharmaceuticals, Inc. (INDV)
CIK:        0001625297
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001193125-26-193925
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indivior Q1 net revenue $317M (+19% YoY); raises FY2026 guidance
----------------------------------------------------------------

- Q1 GAAP net income $89M ($0.69 EPS); non-GAAP net income $123M ($0.96 EPS).
- SUBLOCADE net revenue $232M (+32% YoY) driven by 20% dispense unit growth.
- Record Q1 adjusted EBITDA $164M (+112% YoY); cash and investments $201M.
- Raised FY2026 guidance: net revenue $1.215-1.285B; adj. EBITDA $620-660M.
- Discontinued INDV-6001 development; INDV-2000 failed Ph2 OUD endpoint.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625297/000119312526193925/0001193125-26-193925-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625297/000119312526193925/d40828d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-193925

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer